is now

Like many other biopharma companies, BiOrion has been unable to escape the deteriorating investment climate in pharma biotech over the past year.
However, some of BiOrion’s founders are convinced that patients with fibrotic conditions who can soon be treated with the latest drugs can greatly benefit from BiOrion’s pipeline of fibrogenesis-targeted PET-imaging diagnostics.
That is why we have decided to take over assets and know-how from BiOrion and transfer them to our new company Cortalix.

Within Cortalix, we will also further expand our pipeline of PET-imaging diagnostics and targeted radiotherapeutics and we will also make our platform for single domain antibodies available to our customers.